Baseline characteristics of the overall RTR population and according to groups based on the MDS
| Overall RTR (n=468) | Group 1 MDS 0–4 (n=217) | Group 2 MDS 5–9 (n=251) | p Value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 51.3±13.2 | 49.9±13.9 | 52.5±12.4 | 0.03 |
| Male gender, n (%) | 265 (56.6) | 124 (57.1) | 141 (56.2) | 0.83 |
| Smoking behavior (current smoker), n (%) | 60 (12.8) | 29 (13.4) | 31 (12.4) | 0.64 |
| Total energy intake, kcal/day | 2199±656 | 2168±696 | 2225±619 | 0.35 |
| Physical activity score (time×intensity) | 5605 (2885–8647) | 5060 (2070–8385) | 6000 (3480–8700) | 0.03 |
| Weight, kg | 78.9±15.8 | 78.1±16.2 | 79.6±15.5 | 0.31 |
| Body composition | ||||
| Height, cm | 173.9±9.7 | 173.4±10.6 | 174.3±9.0 | 0.30 |
| BMI, kg/m2 | 26.0±4.5 | 25.9±4.6 | 26.1±4.5 | 0.60 |
| Waist circumference, cm | ||||
| Men | 99.1±12.1 | 98.7±12.2 | 99.5±12.1 | 0.98 |
| Women | 93.0±15.8 | 92.6±15.3 | 93.4±16.3 | 0.68 |
| Circulation | ||||
| Heart rate, bpm | 67.6±12.0 | 67.8±12.3 | 67.4±11.8 | 0.72 |
| SBP, mm Hg | 135.3±17.0 | 135.7±16.3 | 135.0±17.7 | 0.68 |
| DBP, mm Hg | 83.0±11.0 | 83.3±11.1 | 82.8±11.0 | 0.61 |
| Renal function | ||||
| eGFR, mL/min per 1.73 m2 | 53.1±20.2 | 52.3±21.6 | 53.7±18.8 | 0.45 |
| Laboratory parameters | ||||
| Triglycerides, mmol/L | 1.6 (1.2–2.1) | 1.7 (1.2–2.3) | 1.5 (1.1–2.0) | 0.04 |
| HDL cholesterol, mmol/L | 1.4±0.5 | 1.4±0.4 | 1.5±0.5 | 0.001 |
| Fasting glucose, mmol/L | 5.1 (4.7–5.5) | 5.1 (4.7–5.5) | 5.0 (4.7–5.5) | 0.51 |
| Hepatitis C virus, n (%) | 6 (1.3) | 3 (1.4) | 3 (1.2) | 0.86 |
| Cytomegalovirus, n (%) | ||||
| Primary infection | 99 (21.2) | 48 (22.1) | 51 (20.3) | 0.63 |
| Reactivation | 80 (17.1) | 38 (17.5) | 42 (16.7) | 0.69 |
| Primary renal disease | ||||
| Polycystic kidney disease, n (%) | 103 (22.0) | 47 (21.7) | 56 (22.3) | 0.87 |
| Nephrosclerosis, n (%) | 139 (29.7) | 67 (30.9) | 72 (28.7) | 0.61 |
| Transplant characteristics | ||||
| Transplant vintage, years | 5.6 (2.1–12.3) | 5.2 (2.2–12.3) | 5.8 (1.8–12.3) | 0.80 |
| Living donor, n (%) | 168 (35.9) | 70 (32.3) | 98 (39.0) | 0.20 |
| Pre-emptive transplant, n (%) | 84 (17.9) | 32 (14.7) | 52 (20.7) | 0.09 |
| Dialysis duration, months | 37.0 (16.0–60.0) | 46.0 (15.0–63.0) | 32.0 (17.0–56.0) | 0.30 |
| Age donor, years | 43.0±15.5 | 42.6±15.0 | 43.4±15.9 | 0.61 |
| Cold ischemia time, hours | 14.0 (3.0–21.0) | 16.0 (3.0–21.0) | 12.0 (3.0–21.0) | 0.06 |
| Warm ischemia time, minutes | 40 (33–50) | 42 (33–51) | 39 (34–48) | 0.25 |
| Acute rejection, n (%) | 114 (24.4) | 49 (22.6) | 65 (25.9) | 0.41 |
| Medication | ||||
| Cyclosporine, n (%) | 178 (38.0) | 82 (37.8) | 96 (38.2) | 0.92 |
| Tacrolimus, n (%) | 79 (16.9) | 44 (20.3) | 35 (13.9) | 0.07 |
| mTOR inhibitor, n (%) | 5 (1.1) | 2 (0.9) | 3 (1.2) | 0.76 |
| Prednisolone dose, mg | 10.0 (7.5–10.0) | 10.0 (7.5–10.0) | 10.0 (7.5–10.0) | 0.70 |
| Cumulative prednisolone dose, g | 18.3 (7.4–38.1) | 18.3 (7.8–36.6) | 18.2 (7.4–40.4) | 0.86 |
| Diuretics, n (%) | 158 (33.8) | 76 (35.0) | 82 (32.7) | 0.59 |
| β blocker, n (%) | 284 (60.7) | 126 (58.1) | 158 (62.9) | 0.28 |
| ACE inhibitor, n (%) | 158 (33.8) | 73 (33.6) | 85 (33.9) | 0.96 |
| Angiotensin II receptor blocker, n (%) | 71 (15.2) | 39 (18.0) | 32 (12.7) | 0.12 |
| Statins, n (%) | 232 (49.6) | 100 (46.1) | 132 (52.6) | 0.15 |
Data are represented as mean±SD, median (IQR) or n (%). Differences were tested by t-test or Mann-Whitney U test for continuous variables and with χ2 test for categorical variables.
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; MDS, Mediterranean Diet Score; RTR, renal transplant recipients; SBP, systolic blood pressure.